Swedish Orphan Biovitrum AB (SOBI) Stock Forecast & Price Target

Compare

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SOBI Analyst Ratings

Strong Buy

3 Buy

1 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Swedish

Orphan Biovitrum AB

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SOBI Stock 12 Month Forecast

Average Price Target

kr481.67

▲(17.48% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Swedish Orphan Biovitrum AB in the last 3 months. The average price target is kr481.67 with a high forecast of kr500.00 and a low forecast of kr470.00. The average price target represents a 17.48% change from the last price of kr410.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"263":"kr263","382":"kr382","501":"kr501","322.5":"kr322.5","441.5":"kr441.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr500.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":481.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr481.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":470,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr470.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[263,322.5,382,441.5,501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,345.6,357.4769230769231,369.3538461538462,381.2307692307692,393.10769230769233,404.9846153846154,416.8615384615385,428.73846153846154,440.61538461538464,452.4923076923077,464.3692307692308,476.24615384615385,488.12307692307695,{"y":500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,345.6,356.0669230769231,366.5338461538462,377.00076923076927,387.46769230769235,397.9346153846154,408.4015384615385,418.8684615384616,429.33538461538467,439.80230769230775,450.26923076923083,460.73615384615385,471.20307692307694,{"y":481.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,345.6,355.1692307692308,364.73846153846154,374.3076923076923,383.8769230769231,393.44615384615383,403.0153846153846,412.5846153846154,422.1538461538462,431.7230769230769,441.2923076923077,450.86153846153843,460.4307692307692,{"y":470,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":335.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":315.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":293,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":305,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":264.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":283,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":341,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":332.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":345.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr500.00

Average Price Targetkr481.67

Lowest Price Targetkr470.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Shirley Chen

Barclays

kr395→kr470

Buy

14.63%

Upside

Reiterated

02/24/26

Swedish Orphan Biovitrum price target raised to SEK 470 from SEK 395 at BarclaysSwedish Orphan Biovitrum price target raised to SEK 470 from SEK 395 at Barclays

Harry Gillis

Berenberg Bank

kr470→kr500

Buy

21.95%

Upside

Reiterated

02/20/26

Berenberg Bank Keeps Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)

Kirsty Ross Stewart

Exane BNP Paribas

kr475

Buy

15.85%

Upside

Upgraded

02/10/26

Swedish Orphan upgraded to Outperform from Underperform at BNP ParibasSwedish Orphan upgraded to Outperform from Underperform at BNP Paribas

Jon Berggren

Kepler Capital

kr350

Buy

-14.63%

Downside

Reiterated

10/21/25

Kepler Capital Keeps Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)

Alistair Campbell

RBC Capital

kr345→kr350

Buy

-14.63%

Downside

Reiterated

07/22/25

RBC Capital Sticks to Its Buy Rating for Swedish Orphan Biovitrum AB (0MTD)

Emmanuel Papadakis

Deutsche Bank

kr285

Hold

-30.49%

Downside

Upgraded

07/08/25

Swedish Orphan Biovitrum AB (0MTD) was upgraded to a Hold Rating at Deutsche Bank

Patrik Ling

DNB Markets

kr365

Buy

-10.98%

Downside

Reiterated

04/03/25

DNB Markets Reiterates Buy Rating on Swedish Orphan Bio (SOBI:SS) (SWTUY)DNB Markets analyst Patrik Ling reiterated a Buy rating and SEK365.00 price target on Swedish Orphan Bio (SOBI:SS) (OTC: SWTUY).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Shirley Chen

Barclays

kr395→kr470

Buy

14.63%

Upside

Reiterated

02/24/26

Swedish Orphan Biovitrum price target raised to SEK 470 from SEK 395 at BarclaysSwedish Orphan Biovitrum price target raised to SEK 470 from SEK 395 at Barclays

Harry Gillis

Berenberg Bank

kr470→kr500

Buy

21.95%

Upside

Reiterated

02/20/26

Berenberg Bank Keeps Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)

Kirsty Ross Stewart

Exane BNP Paribas

kr475

Buy

15.85%

Upside

Upgraded

02/10/26

Swedish Orphan upgraded to Outperform from Underperform at BNP ParibasSwedish Orphan upgraded to Outperform from Underperform at BNP Paribas

Jon Berggren

Kepler Capital

kr350

Buy

-14.63%

Downside

Reiterated

10/21/25

Kepler Capital Keeps Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)

Alistair Campbell

RBC Capital

kr345→kr350

Buy

-14.63%

Downside

Reiterated

07/22/25

RBC Capital Sticks to Its Buy Rating for Swedish Orphan Biovitrum AB (0MTD)

Emmanuel Papadakis

Deutsche Bank

kr285

Hold

-30.49%

Downside

Upgraded

07/08/25

Swedish Orphan Biovitrum AB (0MTD) was upgraded to a Hold Rating at Deutsche Bank

Patrik Ling

DNB Markets

kr365

Buy

-10.98%

Downside

Reiterated

04/03/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Swedish Orphan Biovitrum AB

3 Months

xxx

Success Rate

8/12 ratings generated profit

Average Return

+6.40%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +6.40% per trade.

1 Year

Jon BerggrenKepler Capital

Success Rate

6/6 ratings generated profit

Average Return

+32.30%

a rating ―

Copying Jon Berggren's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +32.30% per trade.

2 Years

xxx

Success Rate

12/12 ratings generated profit

Average Return

+33.78%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +33.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SOBI Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SOBI has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SOBI average Analyst price target in the past 3 months is 481.67.

Each month's total comprises the sum of three months' worth of ratings.

SOBI Financial Forecast

SOBI Earnings Forecast

Next quarter’s earnings estimate for SOBI is kr3.64 with a range of kr3.19 to kr4.04. The previous quarter’s EPS was kr5.39. SOBI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year SOBI has Performed in-line its overall industry.

SOBI Sales Forecast

Next quarter’s sales forecast for SOBI is kr7.10B with a range of kr6.99B to kr7.25B. The previous quarter’s sales results were kr7.82B. SOBI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year SOBI has Performed in-line its overall industry.

SOBI Stock Forecast FAQ

What is SE:SOBI’s average 12-month price target, according to analysts?

Based on analyst ratings, Swedish Orphan Biovitrum AB’s 12-month average price target is 481.67.

What is SE:SOBI’s upside potential, based on the analysts’ average price target?

Swedish Orphan Biovitrum AB has 17.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Swedish Orphan Biovitrum AB a Buy, Sell or Hold?

Swedish Orphan Biovitrum AB has a consensus rating of Strong Buy, which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.

What is Swedish Orphan Biovitrum AB’s share price target?

The average share price target for Swedish Orphan Biovitrum AB is 481.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr500.00 ,and the lowest forecast is kr470.00. The average share price target represents 17.48% Increase from the current price of kr410.

What do analysts say about Swedish Orphan Biovitrum AB?

Swedish Orphan Biovitrum AB’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Swedish Orphan Biovitrum AB?

To buy shares of SE:SOBI, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Swedish Orphan Biovitrum AB (SOBI) Stock Forecast & Price Target

SOBI Analyst Ratings

SOBI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Swedish Orphan Biovitrum AB

SOBI Analyst Recommendation Trends

SOBI Financial Forecast

SOBI Earnings Forecast

SOBI Sales Forecast

SOBI Stock Forecast FAQ

Detailed List of Analyst Forecasts